American Society of Hematology

Figure 7

$Figure 7. Activity of rhApo2L/TRAIL and rituximab against a rituximab-refractory Ramos NHL variant. A rituximab-refractory variant of Ramos RA1, designated Ramos T1, was established by treatment of Ramos RA1 in vivo with rituximab followed by harvest of tumors that escaped elimination and subsequent culture of cells. Ramos T1 cells were injected subcutaneously into CB17 ICR SCID mice and allowed to establish approximately 200-mm3 tumors. Mice (n = 12 mice/group) were then treated with vehicle (black x), 60 mg/kg rhApo2L/TRAIL (closed blue circle), 4 mg/kg rituximab (open green triangle), 10 mg/kg rituximab (open red square), rhApo2L/TRAIL and 4 mg/kg rituximab (closed green triangle), or rhApo2L/TRAIL and 10 mg/kg rituximab (closed red square). rhApo2L/TRAIL was administered daily for 5 consecutive days followed by a 2-day break and a second 5-day treatment as indicated by the blue bar. Rituximab was administered once a week as indicated by the green arrow.$

Activity of rhApo2L/TRAIL and rituximab against a rituximab-refractory Ramos NHL variant. A rituximab-refractory variant of Ramos RA1, designated Ramos T1, was established by treatment of Ramos RA1 in vivo with rituximab followed by harvest of tumors that escaped elimination and subsequent culture of cells. Ramos T1 cells were injected subcutaneously into CB17 ICR SCID mice and allowed to establish approximately 200-mm³ tumors. Mice (n = 12 mice/group) were then treated with vehicle (black x), 60 mg/kg rhApo2L/TRAIL (closed blue circle), 4 mg/kg rituximab (open green triangle), 10 mg/kg rituximab (open red square), rhApo2L/TRAIL and 4 mg/kg rituximab (closed green triangle), or rhApo2L/TRAIL and 10 mg/kg rituximab (closed red square). rhApo2L/TRAIL was administered daily for 5 consecutive days followed by a 2-day break and a second 5-day treatment as indicated by the blue bar. Rituximab was administered once a week as indicated by the green arrow.

This Feature Is Available To Subscribers Only